Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.

Yazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, Flowers C, Morgan D, Kmieciak M, Bose P, Kimball A, Badros AZ, Baz R, Lin HY, Zhao X, Reich RR, Tombes MB, Shrader E, Sankala H, Roberts JD, Sullivan D, Grant S, Holkova B.

Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):569-575.e1. doi: 10.1016/j.clml.2018.05.023. Epub 2018 Jun 6.

PMID:
30122201
2.

Selective NaV1.1 activation rescues Dravet syndrome mice from seizures and premature death.

Richards KL, Milligan CJ, Richardson RJ, Jancovski N, Grunnet M, Jacobson LH, Undheim EAB, Mobli M, Chow CY, Herzig V, Csoti A, Panyi G, Reid CA, King GF, Petrou S.

Proc Natl Acad Sci U S A. 2018 Aug 21;115(34):E8077-E8085. doi: 10.1073/pnas.1804764115. Epub 2018 Aug 3.

3.

Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterations.

Rutherford SC, Fachel AA, Li S, Sawh S, Muley A, Ishii J, Saxena A, Dominguez PM, Caldas Lopes E, Agirre X, Chambwe N, Correa F, Jiang Y, Richards KL, Betel D, Shaknovich R.

Blood. 2018 Aug 16;132(7):e13-e23. doi: 10.1182/blood-2017-12-821843. Epub 2018 Jul 2.

PMID:
29967128
4.

Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.

Pierpont TM, Limper CB, Richards KL.

Front Oncol. 2018 Jun 4;8:163. doi: 10.3389/fonc.2018.00163. eCollection 2018. Review.

5.

Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired next-generation sequencing assays.

Coombs CC, Gillis NK, Tan X, Berg JS, Ball MC, Balasis ME, Montgomery ND, Bolton K, Parker JS, Mesa TE, Yoder SJ, Hayward MC, Patel NM, Richards KL, Walko CM, Knepper TC, Soper JT, Weiss J, Grilley-Olson JE, Kim WY, Earp S, Levine R, Papaemmanuil E, Zehir A, Hayes DN, Padron E.

Clin Cancer Res. 2018 Jun 4. pii: clincanres.1201.2018. doi: 10.1158/1078-0432.CCR-18-1201. [Epub ahead of print]

PMID:
29866652
6.

Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.

Wang X, Cao X, Sun R, Tang C, Tzankov A, Zhang J, Manyam GC, Xiao M, Miao Y, Jabbar K, Tan X, Pang Y, Visco C, Xie Y, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WWL, van Krieken JH, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Winter JN, Piris MA, Li S, Miranda RN, Medeiros LJ, Li Y, Xu-Monette ZY, Young KH.

Neoplasia. 2018 Jun;20(6):574-593. doi: 10.1016/j.neo.2018.03.002. Epub 2018 May 4.

7.

The YscE/YscG chaperone and YscF N-terminal sequences target YscF to the Yersinia pestis type III secretion apparatus.

Souza CA, Richards KL, Park Y, Schwartz M, Torruellas Garcia J, Schesser Bartra S, Plano GV.

Microbiology. 2018 Mar;164(3):338-348. doi: 10.1099/mic.0.000610. Epub 2018 Feb 5.

PMID:
29458689
8.

Abnormal Cell Sorting Underlies the Unique X-Linked Inheritance of PCDH19 Epilepsy.

Pederick DT, Richards KL, Piltz SG, Kumar R, Mincheva-Tasheva S, Mandelstam SA, Dale RC, Scheffer IE, Gecz J, Petrou S, Hughes JN, Thomas PQ.

Neuron. 2018 Jan 3;97(1):59-66.e5. doi: 10.1016/j.neuron.2017.12.005.

PMID:
29301106
9.

Gene expression and linkage analysis implicate CBLB as a mediator of rituximab resistance.

Jack J, Small GW, Brown CC, Havener TM, McLeod HL, Motsinger-Reif AA, Richards KL.

Pharmacogenomics J. 2018 May 22;18(3):467-473. doi: 10.1038/tpj.2017.41. Epub 2017 Dec 5.

PMID:
29205205
10.

Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.

Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg ML, Nørgaard P, Pedersen M, Gang AO, Høgdall E, Heavican TB, Lone W, Iqbal J, Qin Q, Li G, Kim SY, Healy J, Richards KL, Fedoriw Y, Bernal-Mizrachi L, Koff JL, Staton AD, Flowers CR, Paltiel O, Goldschmidt N, Calaminici M, Clear A, Gribben J, Nguyen E, Czader MB, Ondrejka SL, Collie A, Hsi ED, Tse E, Au-Yeung RKH, Kwong YL, Srivastava G, Choi WWL, Evens AM, Pilichowska M, Sengar M, Reddy N, Li S, Chadburn A, Gordon LI, Jaffe ES, Levy S, Rempel R, Tzeng T, Happ LE, Dave T, Rajagopalan D, Datta J, Dunson DB, Dave SS.

Cell. 2017 Oct 5;171(2):481-494.e15. doi: 10.1016/j.cell.2017.09.027.

PMID:
28985567
11.

Progesterone Sharpens Temporal Response Profiles of Sensory Cortical Neurons in Animals Exposed to Traumatic Brain Injury.

Allitt BJ, Johnstone VPA, Richards KL, Yan EB, Rajan R.

Cell Transplant. 2017 Jul;26(7):1202-1223. doi: 10.1177/0963689717714326.

12.

Escherichia coli "TatExpress" strains super-secrete human growth hormone into the bacterial periplasm by the Tat pathway.

Browning DF, Richards KL, Peswani AR, Roobol J, Busby SJW, Robinson C.

Biotechnol Bioeng. 2017 Dec;114(12):2828-2836. doi: 10.1002/bit.26434. Epub 2017 Oct 6.

13.

Barking up the right tree: advancing our understanding and treatment of lymphoma with a spontaneous canine model.

Villarnovo D, McCleary-Wheeler AL, Richards KL.

Curr Opin Hematol. 2017 Jul;24(4):359-366. doi: 10.1097/MOH.0000000000000357. Review.

14.

Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2.

Moffitt AB, Ondrejka SL, McKinney M, Rempel RE, Goodlad JR, Teh CH, Leppa S, Mannisto S, Kovanen PE, Tse E, Au-Yeung RKH, Kwong YL, Srivastava G, Iqbal J, Yu J, Naresh K, Villa D, Gascoyne RD, Said J, Czader MB, Chadburn A, Richards KL, Rajagopalan D, Davis NS, Smith EC, Palus BC, Tzeng TJ, Healy JA, Lugar PL, Datta J, Love C, Levy S, Dunson DB, Zhuang Y, Hsi ED, Dave SS.

J Exp Med. 2017 May 1;214(5):1371-1386. doi: 10.1084/jem.20160894. Epub 2017 Apr 19.

15.

Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.

Smith SM, Pitcher BN, Jung SH, Bartlett NL, Wagner-Johnston N, Park SI, Richards KL, Cashen AF, Jaslowski A, Smith SE, Cheson BD, Hsi E, Leonard JP.

Lancet Haematol. 2017 Apr;4(4):e176-e182. doi: 10.1016/S2352-3026(17)30028-5. Epub 2017 Mar 15.

16.

The Genetic Basis of Hepatosplenic T-cell Lymphoma.

McKinney M, Moffitt AB, Gaulard P, Travert M, De Leval L, Nicolae A, Raffeld M, Jaffe ES, Pittaluga S, Xi L, Heavican T, Iqbal J, Belhadj K, Delfau-Larue MH, Fataccioli V, Czader MB, Lossos IS, Chapman-Fredricks JR, Richards KL, Fedoriw Y, Ondrejka SL, Hsi ED, Low L, Weisenburger D, Chan WC, Mehta-Shah N, Horwitz S, Bernal-Mizrachi L, Flowers CR, Beaven AW, Parihar M, Baseggio L, Parrens M, Moreau A, Sujobert P, Pilichowska M, Evens AM, Chadburn A, Au-Yeung RK, Srivastava G, Choi WW, Goodlad JR, Aurer I, Basic-Kinda S, Gascoyne RD, Davis NS, Li G, Zhang J, Rajagopalan D, Reddy A, Love C, Levy S, Zhuang Y, Datta J, Dunson DB, Davé SS.

Cancer Discov. 2017 Apr;7(4):369-379. doi: 10.1158/2159-8290.CD-16-0330. Epub 2017 Jan 25.

17.

RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.

Zhang M, Xu-Monette ZY, Li L, Manyam GC, Visco C, Tzankov A, Wang J, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Piris MA, Medeiros LJ, Pham LV, Young KH.

Aging (Albany NY). 2016 Dec 8;8(12):3321-3340. doi: 10.18632/aging.101121.

18.
19.

Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.

Xu-Monette ZY, Li L, Byrd JC, Jabbar KJ, Manyam GC, Maria de Winde C, van den Brand M, Tzankov A, Visco C, Wang J, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Wang M, Hagemeister FB, Piris MA, Han van Krieken J, Medeiros LJ, Li Y, van Spriel AB, Young KH.

Blood. 2016 Dec 29;128(26):3083-3100. doi: 10.1182/blood-2016-05-715094. Epub 2016 Oct 19.

20.

A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma.

Reddy NM, Greer JP, Morgan DS, Chen H, Park SI, Richards KL.

Leukemia. 2017 Jan;31(1):241-244. doi: 10.1038/leu.2016.255. Epub 2016 Sep 22. No abstract available.

21.

Comprehensive genomic characterization of five canine lymphoid tumor cell lines.

Roode SC, Rotroff D, Richards KL, Moore P, Motsinger-Reif A, Okamura Y, Mizuno T, Tsujimoto H, Suter SE, Breen M.

BMC Vet Res. 2016 Sep 17;12:207. doi: 10.1186/s12917-016-0836-z.

22.

Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.

Xia Y, Xu-Monette ZY, Tzankov A, Li X, Manyam GC, Murty V, Bhagat G, Zhang S, Pasqualucci L, Visco C, Dybkaer K, Chiu A, Orazi A, Zu Y, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Piris MA, Westin J, Fowler N, Miranda RN, Ok CY, Li Y, Li J, Medeiros LJ, Young KH.

Leukemia. 2017 Mar;31(3):625-636. doi: 10.1038/leu.2016.243. Epub 2016 Aug 29.

23.

Masking reduces orientation selectivity in rat visual cortex.

Alwis DS, Richards KL, Price NS.

J Neurophysiol. 2016 Nov 1;116(5):2331-2341. doi: 10.1152/jn.00366.2016. Epub 2016 Aug 17.

24.

A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma.

Park SI, Grover NS, Olajide O, Asch AS, Wall JG, Richards KL, Sobol AL, Deal AM, Ivanova A, Foster MC, Muss HB, Shea TC.

Br J Haematol. 2016 Oct;175(2):281-289. doi: 10.1111/bjh.14232. Epub 2016 Jul 22.

25.

The antiepileptic medications carbamazepine and phenytoin inhibit native sodium currents in murine osteoblasts.

Petty SJ, Milligan CJ, Todaro M, Richards KL, Kularathna PK, Pagel CN, French CR, Hill-Yardin EL, O'Brien TJ, Wark JD, Mackie EJ, Petrou S.

Epilepsia. 2016 Sep;57(9):1398-405. doi: 10.1111/epi.13474. Epub 2016 Jul 21.

26.

AMPK Is Essential to Balance Glycolysis and Mitochondrial Metabolism to Control T-ALL Cell Stress and Survival.

Kishton RJ, Barnes CE, Nichols AG, Cohen S, Gerriets VA, Siska PJ, Macintyre AN, Goraksha-Hicks P, de Cubas AA, Liu T, Warmoes MO, Abel ED, Yeoh AE, Gershon TR, Rathmell WK, Richards KL, Locasale JW, Rathmell JC.

Cell Metab. 2016 Apr 12;23(4):649-62. doi: 10.1016/j.cmet.2016.03.008.

27.

Liberation from home mechanical ventilation and decannulation in children.

Henningfeld JK, Maletta K, Ren B, Richards KL, Wegner C, D'Andrea LA.

Pediatr Pulmonol. 2016 Aug;51(8):838-49. doi: 10.1002/ppul.23396. Epub 2016 Feb 25.

PMID:
26934657
28.

CHOP Chemotherapy for Aggressive Non-Hodgkin Lymphoma with and without HIV in the Antiretroviral Therapy Era in Malawi.

Gopal S, Fedoriw Y, Kaimila B, Montgomery ND, Kasonkanji E, Moses A, Nyasosela R, Mzumara S, Varela C, Chikasema M, Makwakwa V, Itimu S, Tomoka T, Kamiza S, Dhungel BM, Chimzimu F, Kampani C, Krysiak R, Richards KL, Shea TC, Liomba NG.

PLoS One. 2016 Mar 2;11(3):e0150445. doi: 10.1371/journal.pone.0150445. eCollection 2016.

29.

Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.

Xu-Monette ZY, Deng Q, Manyam GC, Tzankov A, Li L, Xia Y, Wang XX, Zou D, Visco C, Dybkær K, Li J, Zhang L, Liang H, Montes-Moreno S, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Wang SA, Miranda RN, Piris MA, Winter JN, Medeiros LJ, Li Y, Young KH.

Clin Cancer Res. 2016 Jul 15;22(14):3593-605. doi: 10.1158/1078-0432.CCR-15-2296. Epub 2016 Feb 29.

30.

Insights in Public Health: The Continued Need for Policy, Systems, and Environmental Changes in Hawai'i to Impact Growing Rates of Obesity and Chronic Disease.

Richards KL, Starr RR, Sinclair-White BM, Smith HH, Yamauchi J, Irvin LH.

Hawaii J Med Public Health. 2016 Feb;75(2):52-5. No abstract available.

31.

Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.

Batlle-López A, González de Villambrosía S, Francisco M, Malatxeberria S, Sáez A, Montalban C, Sánchez L, Garcia J, González-Barca E, López-Hernández A, Ruiz-Marcellan MC, Mollejo M, Grande C, Richards KL, Hsi ED, Tzankov A, Visco C, Xu-Monette ZY, Cao X, Young KH, Piris MÁ, Conde E, Montes-Moreno S.

Oncotarget. 2016 Apr 5;7(14):18036-49. doi: 10.18632/oncotarget.7495.

32.

p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.

Xu-Monette ZY, Zhang S, Li X, Manyam GC, Wang XX, Xia Y, Visco C, Tzankov A, Zhang L, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhao X, Møller MB, Parsons BM, Winter JN, Piris MA, Medeiros LJ, Young KH.

Aging (Albany NY). 2016 Feb;8(2):345-65.

33.
34.

Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.

Ye Q, Xu-Monette ZY, Tzankov A, Deng L, Wang X, Manyam GC, Visco C, Montes-Moreno S, Zhang L, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Piris MA, Winter JN, Medeiros LJ, Hu S, Young KH.

Oncotarget. 2016 Jan 19;7(3):2401-16. doi: 10.18632/oncotarget.6262.

35.

Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.

Xu-Monette ZY, Dabaja BS, Wang X, Tu M, Manyam GC, Tzankov A, Xia Y, Zhang L, Sun R, Visco C, Dybkaer K, Yin L, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Zhao X, Winter JN, Piris MA, McDonnell TJ, Miranda RN, Li Y, Medeiros LJ, Young KH.

Mod Pathol. 2015 Dec;28(12):1555-73. doi: 10.1038/modpathol.2015.118. Epub 2015 Nov 6.

36.

Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.

Li L, Xu-Monette ZY, Ok CY, Tzankov A, Manyam GC, Sun R, Visco C, Zhang M, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Wang J, Parsons BM, Winter JN, Piris MA, Pham LV, Medeiros LJ, Young KH.

Oncotarget. 2015 Sep 15;6(27):23157-80.

37.

Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy.

Liu Z, Xu-Monette ZY, Cao X, Manyam GC, Wang X, Tzankov A, Xia Y, Li X, Visco C, Sun R, Zhang L, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Piris MA, Winter JN, O'Malley DP, Medeiros LJ, Young KH.

Mod Pathol. 2015 Oct;28(10):1297-314. doi: 10.1038/modpathol.2015.94. Epub 2015 Aug 7.

38.

Erratum: Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.

Xu-Monette ZY, Tu M, Jabbar KJ, Cao X, Tzankov A, Visco C, Nagarajan L, Cai Q, Montes-Moreno S, An Y, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhao X, Møller MB, Farnen JP, Winter JN, Piris MA, Miranda RN, Medeiros LJ, Young KH.

Oncotarget. 2015 Jun 10;6(16):14720. No abstract available.

39.

Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.

Ok CY, Xu-Monette ZY, Li L, Manyam GC, Montes-Moreno S, Tzankov A, Visco C, Dybkær K, Routbort MJ, Zhang L, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Rao H, Møller MB, Winter JN, Piris MA, Wang SA, Medeiros LJ, Young KH.

Mod Pathol. 2015 Sep;28(9):1202-13. doi: 10.1038/modpathol.2015.76. Epub 2015 Jun 26.

40.

Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary?

Ok CY, Ye Q, Li L, Manyam GC, Deng L, Goswami RR, Wang X, Montes-Moreno S, Visco C, Tzankov A, Dybkaer K, Zhang L, Abramson J, Sohani AR, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhang S, Parsons BM, Xu M, Møller MB, Winter JN, Piris MA, Xu-Monette ZY, Medeiros LJ, Young KH.

Oncotarget. 2015 Jun 10;6(16):13933-45.

41.

Identifying genes that mediate anthracyline toxicity in immune cells.

Frick A, Suzuki OT, Benton C, Parks B, Fedoriw Y, Richards KL, Thomas RS, Wiltshire T.

Front Pharmacol. 2015 Apr 15;6:62. doi: 10.3389/fphar.2015.00062. eCollection 2015.

42.

Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.

Xu-Monette ZY, Tu M, Jabbar KJ, Cao X, Tzankov A, Visco C, Nagarajan L, Cai Q, Montes-Moreno S, An Y, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhao X, Møller MB, Farnen JP, Winter JN, Piris MA, Miranda RN, Medeiros LJ, Young KH.

Oncotarget. 2015 Mar 20;6(8):5615-33. Erratum in: Oncotarget. 2015 Jun 10;6(16):14720. Nagarajan, Lalitha [Added].

43.

The role of screening and monitoring for bleomycin pulmonary toxicity.

Shippee BM, Bates JS, Richards KL.

J Oncol Pharm Pract. 2016 Apr;22(2):308-12. doi: 10.1177/1078155215574294. Epub 2015 Mar 2. Review.

PMID:
25736276
44.

Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.

Chen J, Xu-Monette ZY, Deng L, Shen Q, Manyam GC, Martinez-Lopez A, Zhang L, Montes-Moreno S, Visco C, Tzankov A, Yin L, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhao X, Møller MB, Farnen JP, Winter JN, Piris MA, Pham L, Young KH.

Oncotarget. 2015 Mar 20;6(8):5597-614.

45.

FOXP1 potentiates Wnt/β-catenin signaling in diffuse large B cell lymphoma.

Walker MP, Stopford CM, Cederlund M, Fang F, Jahn C, Rabinowitz AD, Goldfarb D, Graham DM, Yan F, Deal AM, Fedoriw Y, Richards KL, Davis IJ, Weidinger G, Damania B, Major MB.

Sci Signal. 2015 Feb 3;8(362):ra12. doi: 10.1126/scisignal.2005654.

46.

Lenalidomide-associated hemolytic anemia.

Lim MY, Raval JS, Richards KL, Zeidner JF, Foster MC.

Leuk Lymphoma. 2015;56(9):2717-9. doi: 10.3109/10428194.2014.1003558. Epub 2015 Mar 2. No abstract available.

PMID:
25644743
47.

Man's best friend: what can pet dogs teach us about non-Hodgkin's lymphoma?

Richards KL, Suter SE.

Immunol Rev. 2015 Jan;263(1):173-91. doi: 10.1111/imr.12238. Review.

48.

Increased serum tumor necrosis factor α levels in patients with lenalidomide-induced hypothyroidism.

Iams WT, Hames ML, Tsai JP, Dahlman KB, Talbott MS, Richards KL, Reddy NM.

Exp Hematol. 2015 Feb;43(2):74-8. doi: 10.1016/j.exphem.2014.10.009. Epub 2014 Oct 28.

49.

Sodium channel β1 subunit localizes to axon initial segments of excitatory and inhibitory neurons and shows regional heterogeneity in mouse brain.

Wimmer VC, Harty RC, Richards KL, Phillips AM, Miyazaki H, Nukina N, Petrou S.

J Comp Neurol. 2015 Apr 1;523(5):814-30. doi: 10.1002/cne.23715. Epub 2015 Jan 14.

PMID:
25421039
50.

Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs.

Ward MA, Fang G, Richards KL, Walko CM, Earnshaw SR, Happe LE, Blalock SJ.

Curr Med Res Opin. 2015 Feb;31(2):289-97. doi: 10.1185/03007995.2014.991440. Epub 2014 Dec 10.

PMID:
25420131

Supplemental Content

Loading ...
Support Center